Drug intelligence / Profile preview

NV-A01

Development stage: Phase 1
Lead developer: Nanjing Nuowei Biotechnology
Administration: Intratumoral

Overview

NV-A01 is an investigational drug being developed for the treatment of advanced malignant solid tumors, with a primary focus on glioma and glioblastoma. It is currently in Phase 1 clinical trials to evaluate its safety, tolerability, and pharmacokinetic characteristics in patients with advanced brain cancer. The drug is administered via intratumoral injection. NV-A01 is being developed by Nanjing Nuowei Biotechnology Partnership LP[1][3][4][5]. The precise mechanism of action and modality have not been disclosed in public sources.

Beyond the preview

Go deeper on NV-A01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NV-A01.

Explore the full profile